The notices it replaced
- Reissues: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 2 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-12-088.
Who won it before
1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $150,900 in first-year total cost, median $150,900.
Most frequent study sections
- Special Emphasis Panel[ZRG1 ETTN-C (11)]1
Most frequent institutions
- NAPROGENIX, INC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2014 | Novel flavonoids as anti-inflammatory agents in alcoholism1R43AA021038-01 | LITTLETON, JOHN M. | NAPROGENIX, INC, KY | $150,900 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.